BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35477823)

  • 1. Fructose-1,6-bisphosphatase 1 (FBP1) is an independent biomarker associated with a favorable prognosis in esophageal adenocarcinoma.
    Damanakis A; Plum PS; Gebauer F; Schröder W; Büttner R; Zander T; Bruns CJ; Quaas A
    J Cancer Res Clin Oncol; 2022 Sep; 148(9):2287-2293. PubMed ID: 35477823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of fructose 1,6-bisphosphate-mediated glycolysis/gluconeogenesis genes in cancer prognosis.
    Li CH; Chan MH; Chang YC
    Aging (Albany NY); 2022 Apr; 14(7):3233-3258. PubMed ID: 35404841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
    Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
    Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
    [No Abstract]   [Full Text] [Related]  

  • 4. Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma.
    Hirata H; Sugimachi K; Komatsu H; Ueda M; Masuda T; Uchi R; Sakimura S; Nambara S; Saito T; Shinden Y; Iguchi T; Eguchi H; Ito S; Terashima K; Sakamoto K; Hirakawa M; Honda H; Mimori K
    Cancer Res; 2016 Jun; 76(11):3265-76. PubMed ID: 27197151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma.
    Wang B; Fan P; Zhao J; Wu H; Jin X; Wu H
    J Exp Clin Cancer Res; 2018 Sep; 37(1):224. PubMed ID: 30201002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Noncanonical Role of Fructose-1, 6-Bisphosphatase 1 Is Essential for Inhibition of Notch1 in Breast Cancer.
    Lu C; Ren C; Yang T; Sun Y; Qiao P; Wang D; Lv S; Yu Z
    Mol Cancer Res; 2020 May; 18(5):787-796. PubMed ID: 32041737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fructose-1,6-bisphosphatase is a novel regulator of Wnt/β-Catenin pathway in breast cancer.
    Li K; Ying M; Feng D; Du J; Chen S; Dan B; Wang C; Wang Y
    Biomed Pharmacother; 2016 Dec; 84():1144-1149. PubMed ID: 27780144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma.
    Schiffmann LM; Göbel H; Löser H; Schorn F; Werthenbach JP; Fuchs HF; Plum PS; Bludau M; Zander T; Schröder W; Bruns CJ; Kashkar H; Quaas A; Gebauer F
    BMC Cancer; 2019 May; 19(1):531. PubMed ID: 31151416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel variant in the FBP1 gene causes fructose-1,6-bisphosphatase deficiency through increased ubiquitination.
    Liang X; Liu X; Li W; Zhang L; Zhang B; Lai G; Zhao Y
    Arch Biochem Biophys; 2023 Jul; 742():109619. PubMed ID: 37142076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fructose‑1,6‑bisphosphatase‑1 decrease may promote carcinogenesis and chemoresistance in cervical cancer.
    Li H; Li M; Pang Y; Liu F; Sheng D; Cheng X
    Mol Med Rep; 2017 Dec; 16(6):8563-8571. PubMed ID: 28990097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic but not Intestinal FBP1 Is Required for Fructose Metabolism and Tolerance.
    Bai Q; Liu Y; Wang CM; Wang JR; Feng Y; Ma X; Yang X; Shi YN; Zhang WJ
    Endocrinology; 2023 Apr; 164(6):. PubMed ID: 36964915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fructose-1,6-Bisphosphatase 1 Reduces
    Chen R; Li J; Zhou X; Liu J; Huang G
    Radiology; 2017 Sep; 284(3):844-853. PubMed ID: 28387640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human fructose-1,6-bisphosphatase gene (FBP1): exon-intron organization, localization to chromosome bands 9q22.2-q22.3, and mutation screening in subjects with fructose-1,6-bisphosphatase deficiency.
    el-Maghrabi MR; Lange AJ; Jiang W; Yamagata K; Stoffel M; Takeda J; Fernald AA; Le Beau MM; Bell GI; Baker L
    Genomics; 1995 Jun; 27(3):520-5. PubMed ID: 7558035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy.
    Plum PS; Löser H; Zander T; Essakly A; Bruns CJ; Hillmer AM; Alakus H; Schröder W; Büttner R; Gebauer F; Quaas A
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1031-1040. PubMed ID: 33300112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fructose-1,6-bisphosphatase is a nonenzymatic safety valve that curtails AKT activation to prevent insulin hyperresponsiveness.
    Gu L; Zhu Y; Watari K; Lee M; Liu J; Perez S; Thai M; Mayfield JE; Zhang B; Cunha E Rocha K; Li F; Kim LC; Jones AC; Wierzbicki IH; Liu X; Newton AC; Kisseleva T; Lee JH; Ying W; Gonzalez DJ; Saltiel AR; Simon MC; Karin M
    Cell Metab; 2023 Jun; 35(6):1009-1021.e9. PubMed ID: 37084733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinoma.
    Yakirevich E; Lu S; Allen D; Mangray S; Fanion JR; Lombardo KA; Safran H; Resnick MB
    Hum Pathol; 2017 Aug; 66():126-135. PubMed ID: 28666927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression.
    Yang J; Jin X; Yan Y; Shao Y; Pan Y; Roberts LR; Zhang J; Huang H; Jiang J
    Sci Rep; 2017 Mar; 7():43864. PubMed ID: 28262837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. USP44 suppresses pancreatic cancer progression and overcomes gemcitabine resistance by deubiquitinating FBP1.
    Yang C; Zhu S; Yang H; Deng S; Fan P; Li M; Jin X
    Am J Cancer Res; 2019; 9(8):1722-1733. PubMed ID: 31497353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis.
    Liu X; Wang X; Zhang J; Lam EK; Shin VY; Cheng AS; Yu J; Chan FK; Sung JJ; Jin HC
    Oncogene; 2010 Jan; 29(3):442-50. PubMed ID: 19881551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGM2: a cell surface marker in esophageal adenocarcinomas.
    Leicht DT; Kausar T; Wang Z; Ferrer-Torres D; Wang TD; Thomas DG; Lin J; Chang AC; Lin L; Beer DG
    J Thorac Oncol; 2014 Jun; 9(6):872-81. PubMed ID: 24828664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.